Clinical Trial Update: Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating allogeneic bone marrow-derived mesenchymal stem cells to manage heart failure due to anthracycline-induced cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthracycline-induced Cardiomyopathy
• Cardiomyopathy
• Heart Failure

Drugs mentioned

• Allogeneic bone marrow-derived mesenchymal stem cells (bone marrow-derived mesenchymal stem cells)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cardiomyopathy, Heart Failure | Phase 1 | Status: RECRUITING